Synosia Therapeutics Raises $30 Million In Series C Round
Synosia Therapeutics raised $30M in a Series C financing round. UCB was a new investors in the Switzerland-based biotherapeutics company that is focused on neurology and psychiatry. It invested $20 million. Existing investors Versant Ventures, 5Am Ventures, Novo A/S, Aravis Venture, Investor Growth Capital and Swiss Helvetia Fund invested the other $10 million. UCB’s President of North American Operations Greg Duncan and Executive Vice President of Drug Discovery and President of UCB New Medicines Ismail Kola will serve as Synosia directors.
12 October 2010•2 mins read
